195 related articles for article (PubMed ID: 32314468)
1. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis.
Gao CP; Zhang D; Zhang T; Wang JX; Han SX; Graham DY; Lu H
Helicobacter; 2020 Aug; 25(4):e12692. PubMed ID: 32314468
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis.
Gao CP; Zhou Z; Wang JZ; Han SX; Li LP; Lu H
J Dig Dis; 2016 Dec; 17(12):811-819. PubMed ID: 27977071
[TBL] [Abstract][Full Text] [Related]
3. Vonoprazan-amoxicillin dual therapy for
Zhou BG; Mei YZ; Jiang X; Zheng AJ; Ding YB
Saudi J Gastroenterol; 2023; 29(6):347-357. PubMed ID: 37602635
[TBL] [Abstract][Full Text] [Related]
4. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
5. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis.
Wang B; Lv ZF; Wang YH; Wang H; Liu XQ; Xie Y; Zhou XJ
World J Gastroenterol; 2014 Oct; 20(40):14973-85. PubMed ID: 25356059
[TBL] [Abstract][Full Text] [Related]
6. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis.
Li C; Shi Y; Suo B; Tian X; Zhou L; Song Z
Helicobacter; 2021 Aug; 26(4):e12816. PubMed ID: 34002433
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Zhou BG; Jiang X; Ding YB; She Q; Li YY
Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
[TBL] [Abstract][Full Text] [Related]
8. Treatment of
Kanu JE; Soldera J
World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
[TBL] [Abstract][Full Text] [Related]
9. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
[TBL] [Abstract][Full Text] [Related]
10. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
Yu L; Luo L; Long X; Liang X; Ji Y; Graham DY; Lu H
Helicobacter; 2019 Aug; 24(4):e12596. PubMed ID: 31111580
[TBL] [Abstract][Full Text] [Related]
11. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.
Goh KL; Manikam J; Qua CS
Aliment Pharmacol Ther; 2012 May; 35(9):1097-102. PubMed ID: 22404486
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori eradication with high-dose proton pump inhibitor-amoxicillin dual therapy: A systematic review and meta-analysis.
Yeh JA; Huang HK; Chou AL; Lin HJ; Feng CL; Kuo CJ; Lai CH
Int J Antimicrob Agents; 2024 Jun; 63(6):107159. PubMed ID: 38554984
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials.
Zhang M; Pang M; Zhang M
Clinics (Sao Paulo); 2022; 77():100058. PubMed ID: 35810638
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.
Gisbert JP; Gonzalez L; Calvet X
Helicobacter; 2005 Jun; 10(3):157-71. PubMed ID: 15904473
[TBL] [Abstract][Full Text] [Related]
15. The influence of pretreatment with PPI on Helicobacter pylori eradication: A systematic review and meta-analysis.
Kuang S; Xu J; Chen M; Zhang Y; Shi F; Lu X
Medicine (Baltimore); 2021 Nov; 100(47):e27944. PubMed ID: 34964772
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial.
Zhang Y; Zhu YJ; Zhao Z; Zhao JT; Wang TY; Yang J; Chen DF; Lan CH
Eur J Gastroenterol Hepatol; 2020 May; 32(5):563-568. PubMed ID: 31851093
[TBL] [Abstract][Full Text] [Related]
17. Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
Ju KP; Kong QZ; Li YY; Li YQ
Helicobacter; 2024; 29(1):e13054. PubMed ID: 38900537
[TBL] [Abstract][Full Text] [Related]
18. Second-line rescue treatment of
Lin TF; Hsu PI
World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
[TBL] [Abstract][Full Text] [Related]
19. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of
Zhang C; Zhang J; Cheng YJ
Saudi J Gastroenterol; 2023; 29(2):88-94. PubMed ID: 36960527
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.
Feng JH; Cheng J; Lao YJ; Huang K; Mou JL; Hu F; Lin ML; Lin J
Eur J Med Res; 2023 Aug; 28(1):272. PubMed ID: 37550781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
